Design of the Swiss Atrial Fibrillation Cohort Study (Swiss-AF): structural brain damage and cognitive decline among patients with atrial fibrillation.

Détails

Ressource 1Télécharger: 28695548.pdf (956.72 [Ko])
Etat: Public
Version: Final published version
ID Serval
serval:BIB_D0DD094B0509
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Design of the Swiss Atrial Fibrillation Cohort Study (Swiss-AF): structural brain damage and cognitive decline among patients with atrial fibrillation.
Périodique
Swiss medical weekly
Auteur(s)
Conen D., Rodondi N., Mueller A., Beer J., Auricchio A., Ammann P., Hayoz D., Kobza R., Moschovitis G., Shah D., Schlaepfer J., Novak J., di Valentino M., Erne P., Sticherling C., Bonati L., Ehret G., Roten L., Fischer U., Monsch A., Stippich C., Wuerfel J., Schwenkglenks M., Kuehne M., Osswald S.
ISSN
1424-3997 (Electronic)
ISSN-L
0036-7672
Statut éditorial
Publié
Date de publication
11/07/2017
Peer-reviewed
Oui
Volume
147
Pages
w14467
Langue
anglais
Notes
Publication types: Journal Article ; Multicenter Study
Publication Status: epublish
Résumé
Several studies found that patients with atrial fibrillation (AF) have an increased risk of cognitive decline and dementia over time. However, the magnitude of the problem, associated risk factors and underlying mechanisms remain unclear.
This article describes the design and methodology of the Swiss Atrial Fibrillation (Swiss-AF) Cohort Study, a prospective multicentre national cohort study of 2400 patients across 13 sites in Switzerland. Eligible patients must have documented AF. Main exclusion criteria are the inability to provide informed consent and the presence of exclusively short episodes of reversible forms of AF. All patients undergo extensive phenotyping and genotyping, including repeated assessment of cognitive functions, quality of life, disability, electrocardiography and cerebral magnetic resonance imaging. We also collect information on health related costs, and we assemble a large biobank. Key clinical outcomes in Swiss-AF are death, stroke, systemic embolism, bleeding, hospitalisation for heart failure and myocardial infarction. Information on outcomes and updates on other characteristics are being collected during yearly follow-up visits.
Up to 7 April 2017, we have enrolled 2133 patients into Swiss-AF. With the current recruitment rate of 15 to 20 patients per week, we expect that the target sample size of 2400 patients will be reached by summer 2017.
Swiss-AF is a large national prospective cohort of patients with AF in Switzerland. This study will provide important new information on structural and functional brain damage in patients with AF and on other AF related complications, using a large variety of genetic, phenotypic and health economic parameters.

Mots-clé
Aged, Atrial Fibrillation/complications, Atrial Fibrillation/pathology, Atrial Fibrillation/psychology, Brain/diagnostic imaging, Brain/pathology, Brain Diseases/diagnostic imaging, Brain Diseases/etiology, Brain Diseases/psychology, Clinical Protocols, Cognitive Dysfunction/diagnostic imaging, Cognitive Dysfunction/etiology, Electrocardiography, Female, Genotype, Humans, Magnetic Resonance Imaging/methods, Male, Middle Aged, Prospective Studies, Quality of Life, Research Design, Risk Factors, Switzerland
Pubmed
Web of science
Open Access
Oui
Création de la notice
17/07/2017 10:24
Dernière modification de la notice
20/08/2019 16:51
Données d'usage